- Previous Close
5.12 - Open
5.10 - Bid 3.67 x 200
- Ask 6.54 x 200
- Day's Range
5.09 - 5.13 - 52 Week Range
3.18 - 16.94 - Volume
355,830 - Avg. Volume
871,922 - Market Cap (intraday)
230.932M - Beta (5Y Monthly) 2.51
- PE Ratio (TTM)
-- - EPS (TTM)
-1.09 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.68
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novartis Pharma AG. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.
www.thirdharmonicbio.comRecent News: THRD
View More
Performance Overview: THRD
Trailing total returns as of 4/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: THRD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: THRD
View MoreValuation Measures
Market Cap
230.93M
Enterprise Value
-50.92M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.81
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-12.86%
Return on Equity (ttm)
-16.41%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-45.47M
Diluted EPS (ttm)
-1.09
Balance Sheet and Cash Flow
Total Cash (mrq)
285.06M
Total Debt/Equity (mrq)
1.13%
Levered Free Cash Flow (ttm)
-26.19M
Research Analysis: THRD
View MoreResearch Reports: THRD
View MoreDaily – Vickers Top Buyers & Sellers for 11/01/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/23/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 09/20/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.